Currently Viewing:
American Society of Hematology Annual Meeting & Exposition
Research to Look Out for at ASH 2018
November 26, 2018
Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings
December 01, 2018
Studies at ASH Evaluate Episodic ED Utilization, Adherence, QOL in Sickle Cell Disease
December 01, 2018
Dr Theresa Keegan: AYAs Continue to Be Underrepresented in Clinical Trials
December 01, 2018
Dr Elizabeth Griffiths: Mutational Data Help Inform Clinical Prognosis, Treatment Protocol in AML
December 01, 2018
Length of Hospital Stay Key Driver of Costs Associated With CRS Following CAR T Treatment
December 02, 2018
Dr Jeff Sharman Discusses Standard of Care for CLL Based on Treatment Setting
December 03, 2018
Dr Alison Moskowitz on the Importance of Patients Understanding Their Diagnosis, Treatment Options
December 03, 2018
Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL
December 03, 2018
ASH-EHA Joint Symposium Dives Deep Into the Leukemia–Down Syndrome Connection
December 03, 2018
iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL
December 03, 2018
Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome
December 03, 2018
Dr Robert Rifkin Outlines Recent Treatment Advances in Multiple Myeloma
December 03, 2018
NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward
December 18, 2018
Dr Jeff Sharman: Cost of Therapy Is a Major Challenge in CLL
January 06, 2019
Dr Theresa Keegan on Barriers, Facilitators to Clinical Trial Participation Among AYAs
January 07, 2019
Dr Jennifer Brown on the Role of Genomic Sequencing in CLL
January 08, 2019
Dr Robert Rifkin Discusses Barriers, Biomarkers in Multiple Myeloma
January 10, 2019
Currently Reading
Dr Robert Rifkin on Lack of Education Surrounding Biosimilars
January 22, 2019

Dr Robert Rifkin on Lack of Education Surrounding Biosimilars

Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.


Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.

Transcript

What are the biggest barriers facing biosimilars in oncology?


Biosimilars are interesting because of the multiplicity of stakeholders and the about of education you need to do. We found that even with these being out there for a while, and several being approved, there’s still a dramatic lack of education amongst the stakeholders. There are a number of barriers to adoption, whether it’s educating the providers, educating the patients, educating the payers. And then all of the market dynamics.

I think the barriers are falling as we get more and more molecules out there, but there’s still a huge amount of education that needs to be done for all the stakeholders.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up